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Abstract
Background: Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition with an
unclear pathophysiological mechanism affecting different parts of the body. If untreated, the disease can lead to
fibrosis and irreversible organ damage. IgG4-RD mostly has been described in adults, hence it is generally unknown
among pediatricians. This systematic search of the literature provides an overview of all reports published on IgG4-
RD in children in order to create awareness of IgG4-RD in pediatrics and to emphasize the broad clinical
presentation of this disease.
Methods: A systematic literature search of Embase, Medline, Web-of-Science, PubMed publisher, Cochrane and
Google Scholar was performed for case reports on IgG4-RD in children.
Results: Of total 740 articles identified by the search, 22 case reports including 25 cases of IgG4-RD in children
were found. The median age of the children was 13 years, of which 64 % were girls. IgG4-related orbital disease
(44 %) and autoimmune pancreatitis type 1/IgG4-related pancreatitis (12 %) predominantly occurred. Less
frequently, other manifestations as pulmonary manifestation, cholangitis and lymphadenopathy were also found.
Almost all cases were histologically proven. Prednisone was the first choice of treatment leading to favorable
clinical response in 83 % of the cases. Maintenance therapy with steroid sparing agents was required in 43 % of the
cases needing therapy. Rituximab was successful in all 4 cases, whereas, the disease modifying rheumatic drugs
(DMARDs) mycophenolate mofetil, azathioprine and methotrexate were effective in almost 50 % of the cases.
Conclusion: IgG4-RD in children is a generally unknown disease among pediatricians, but several pediatric cases
have been described. Prednisone is the first choice of treatment leading to disease remission in the majority of the
cases. DMARDs and rituximab are alternative effective steroid sparing agents with more positive evidence for the
latter.
Background
IgG4-RD is a systemic fibro-inflammatory disease affecting
different parts of the body [1]. The disease is characterized
by tumour-like infiltrations of IgG4 positive plasma cells in
the tissues, mostly with fibrotic abnormalities and often ele-
vated serum IgG4 levels [1]. The underlying pathophysio-
logical mechanism of IgG4-RD is still unclear, but when
untreated, the disease can lead to irreversible organ damage
because of the fibrosis. Early recognition and therapy is
therefore critical [2, 3]. In recent time there has been a lot
of attention to IgG4-RD in adult care leading to evolving
knowledge about pathogenesis, diagnosis and treatment of
this disease. However, further studies are required to pro-
vide more insight into this disease, in particular, the under-
lying pathogenesis has yet to be clarified. The average age
at which IgG4-RD can occur, is estimated to be older than
50 years [1, 4]. Although case reports are available on
IgG4-RD in children [5, 6], no pediatric studies or reviews
about this disease have been published yet. Knowledge and
awareness of this disease is essential to prevent missing the
diagnosis and subsequent delay of treatment, especially in
children.
We performed a systematic literature search in order
to make an overview of all the case reports that have
been published regarding IgG4-RD in children. The
main purpose of this study was to create awareness of
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IgG4-RD in pediatrics and to emphasize the broad clin-
ical presentation of this disease. Furthermore, with the
current knowledge about the disease we wanted to pro-
vide an overview on epidemiology, pathogenesis and
treatment of this disease for the pediatricians.
Methods
A systematic literature search was conducted to provide
an overview of all case reports and (if available) case
series regarding IgG4-RD in pediatrics. The study was
performed and reported in accordance with the PRISMA
statement for systematic reviews.
Data source, study selection and data extraction
Relevant articles on IgG4-RD in children were retrieved
from Embase.com, Medline (Ovid), Web-of-Science, and
the Cochrane Library from inception to last date of inclu-
sion July 16th 2015. Additional references were obtained
from PubMed (the subset as supplied by publisher, con-
taining references not yet indexed in Medline) and Google
Scholar (the most relevant citations). No filters for date or
language were used in the search strategy. See the add-
itional Appendix for the full search strategies for all
databases. Two authors reviewed and extracted the data
independently.
Results
Of a total of 740 articles identified by the search, 34 arti-
cles on IgG4-RD in pediatrics were eligible (Fig. 1). After
screening, 22 case reports on IgG4-RD in children were
identified. Three articles described two pediatric patients
leading to a total of 25 cases of IgG4-RD [7–9]. The
main outcomes of this study are demonstrated in
Table 1.
Patients
With this systematic literature review we identified 22
case reports of IgG-RD in children. Identified studies
were published over a 5-year span (2010–2015). The
case reports included patients aged ranging from
22 months to 17 years of age. The median age of the
children in this study was 13 years and 64 % of the chil-
dren were girls.
Organ manifestation
The cases described in this study show a spectrum of
different organ manifestations (Fig. 2) of IgG4-RD.
Records identified  through
database searching
(n = 740)
S
cr
ee
n
in
g
In
cl
u
d
ed
E
lig
ib
ili
ty
Id
en
ti
fi
ca
ti
o
n
Additional records identified
through others ources
(n = 0)
Records after duplicates removed
(n = 452)
Eligible articles on IgG4-RD
in pediatrics
(n = 34)
Full text articlesexcluded
(n = 12)
Review on AIP (n = 3)
Duplicates (n = 1)
Non-IgG4-RD (n = 5)
IgG4-RD adult (n = 1)
Rosai-Dorfman disease(n = 1)
ALK1 positive inflammatory
myofibroblastic tumor (n = 1)
Articlesincluded
(n = 22 with 25 cases)*
Records excluded based
on title and abstract
(n = 418)
Fig. 1 Search strategy and selection of the articles. * Three articles demonstrated each two cases of IgG4-RD in children. Therefore, a total of 25
cases were available for this study
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Table 1 Outcomes reported in case reports on IgG4-RD in pediatrics
Reference Age Sex Organ manifestation Serum IgG4 Therapy Comments
Miglani 2010 [24] 13y M AIP-1H+ El (603 mg/dl) Pred 20 mg/d Initially suspected of
malignancy. Pred tapered
and stopped in 4 months.
Ibrahim 2010 [25] 3y F IgG4-R cholangitisH+ El (258 mg/dl) Pred 2 mg/kg/d
and Aza 1.5 mg/kg
Relapse after tapering pred
and required a low (2 mg/d)
maintenance dose of pred and Aza.
Mannion 2010 [14] 13y F AIP-1 and IgG4-R fibrosing
mediastinitis, renal and
hepatic manifestationH+
El (73.4 mg/dl) Pred and MMF Good results by MMF, pred tapered
and stopped successfully.
Zakeri 2011 [20] 17y M Riedel’s thyroiditisH + a NM Pred 40 mg/d Pred tapered and stopped in 3 months.
Melo 2012 [28] 11y M IgG4-R sialadenitisH+ NM Pred
Griepentrog 2013 [7] 10y F IgG4-RODH+ N (L U) Lateral orbitotomy No further treatment was required.
Griepentrog 2013 [7] 14y F IgG4-RODH+ N (L U) Pred, dosage
unknown, and
MMF
MMF because of relapse after
tapering pred, successful.
Kalapesi 2013 [10] 5y F IgG4-RODH+ El (1.52 g/l) Pred 1 mg/kg and
MMF (600 mg/m2)
Weaned off pred and maintained
on MMF successfully.
Naghibi 2013 [15] 16y F IgG4-related colitis,
in the past AIP-1H+
El (210 mg/dl) Adalimumab Refractory disease to pred 0.5 mg/kg,
Aza and infliximab. Adalimumab successful.
Pifferi 2013 [26] 15y M IgG4-R pulmonary
diseaseH+
El (1090 mg/dl) Pred 0.6 mg/kg/d Treatment for 4 weeks.
Sane 2013 [11] 12y F IgG4-ROD and nephrotic
syndromeH+
N (L U) Methylpred and
rituximab
The nephrotic syndrome also
resolved. Initial good response
to pred 40 mg, but relapse occured.
Pasic 2013 [12] 10y F Mikulicz disease/
IgG-RODH+
EL 9.02 g/l NM
Caso 2013 [16] 17y M IgG4-R lymphad and
scleritisH+
El (4.43 g/l) Rituximab and
pred 10 mg daily
Refractory to MMF, good
results with rituximab.
Hasosah 2014 [17] 7y F IgG4-R mesenteritis and
pericarditisH+
El (149 mg/dl) Pred, aza and
colchicine
(doses unknown)
Relapsed despite aza, further
treatment with 5 mg prednisone
as maintenance therapy.
Jariwala 2014 [5] 7y M IgG4-RODH+ El (109.3 mg/dl) Pred 1 mg/kg/d
and Aza 2 mg/kg/d
Good clinical results.
Mittal 2014 [6] 14y M IgG4-RODH+ El (4.3 g/l) Pred 0.6 mg/kg/d Initial improvement, but lost to follow-up.
Notz 2014 [29] 13y F IgG4-R dacryoadenitisH+ N (23.9 mg/dl) Pred 40 mg/d for
3 months
Prabhu 2015 [8] 15y F IgG4-ROD and sinonasal
diseaseH+
El (579 mg/dl) Rituximab Insufficient response to prednisone.
Prabhu 2015 [8] 15 y F IgG4-R sinonasal diseaseH
+
El (206 mg/dl) Pred (dosage
unknown)
Batu 2015 [9] 14y F IgG4-RODH+ N (7.5 g/l)(0-12.5 g/l) Pred (dosage
unknown)
Pred was tapered and stopped, MTX as
maintenance therapy.
Batu 2015 [9] 9y F IgG4-RODH+ N (3.7 g/l) Methylpred and
cyclophosphamide
No response to pred, MTX or MMF.
Now stable disease.
Corujeira 2015 [18] 22Mo F IgG4-R pulmonary disease
and IgG4-R lymphadH+
El (805 mg/dl) Pred 2 mg/kg/d Pred tapered over period of 6 months.
Gillispie 2015 [13] 7y F IgG4-ROD, nerve and
renal diseaseH+
N (L U) Pred and
rituximab
Refractory to pred, responsive to rituximab.
Nada 2015 [19] 10y M IgG4-R hepatic mass and
coagulopathyH+
El (420 mg/dl) Pred 2 mg/kg/d Coagulopathy also resolved after
treatment.
Rosen 2015 [27] 17y M IgG4-R cholangitisH+ El (242 mg/dl) Pred 30 mg/d Pred weaned in 3 months.
Y year, IgG4-ROD IgG4-related orbital disease, Mo months, H+ histology performed, Mikulicz disease IgG4-related orbital and submandibular disease, M male, AIP-1
autoimmune pancreatitis type 1, IgG-R IgG4-related disease, F female, Pred prednisone, Aza azathioprine, EL elevated, MMF mycophenolate mofetil, L U level unknown, N
normal, NM not measured, Methylpred Methylprednisolone, Lymphad Lymphadenopathy
aHistology without IgG4 staining
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However, most of the cases report IgG4-related orbital
disease (IgG4-ROD) (44 %) [5–13]. Other manifestations
were IgG4-related pancreatitis/autoimmune pancreatitis
type 1 (AIP 1) (12 %), IgG4-related cholangitis (8 %),
IgG4-related pulmonary disease (8 %), and the remaining
cases (28 %) were single cases of Riedel’s thyroiditis/
IgG4-related thyroid disease, IgG4-related sialadenitis,
IgG4-related mesenteritis, IgG4-related lymphadenop-
athy, IgG4-related dacryoadenitis, IgG4-related sinonasal
disease and IgG4-related hepatic mass. Kidney involve-
ment was seen in three cases in combination with other
organ manifestations [11, 13, 14]. Systemic IgG4-RD
(two or more organ manifestations) occurred in 40 % of
the cases [8, 11–19].
Diagnosis
In this study, all cases of IgG4-RD were histologically con-
firmed, except one case of Riedel’s thyroiditis [20],
whereby histology was performed without IgG4 staining.
Riedel’s thyroiditis is recently included in the spectrum of
IgG4-RD [21], therefore we decided to include this case
report in this study. Furthermore, despite the presence of
IgG4 positive plasma cells in the tissue, two case reports
concerning Rosai-Dorfman disease and ALK-1 positive in-
flammatory myofibroblastic tumor [22, 23] were excluded,
because according to Boston consensus these diseases
should not be considered as IgG4-RD. Serum IgG4 was
measured in 23 of the 25 cases, and was found to be ele-
vated in 16 cases [5, 6, 8, 10, 12, 14–19, 24–27] (70 %).
Therapy
Prednisone was the first choice of treatment in 23 of the
25 cases [5–11, 14–20, 24–29]. In one case no treatment
was initiated or mentioned [12], and in another case sur-
gery alone resulted in complete remission [7].
The doses of prednisone that was used were not
mentioned in all cases, but when specified was usually
between 0.5 and 2 mg/kg/day. Prednisone therapy re-
sulted in a rapid response in 19 of the 23 cases treated
[5–11, 13, 14, 17–20, 24–29]. Prednisone alone in-
duced remission and could be tapered and discontin-
ued without relapse in 10 of the cases (43 %), and thus
was the sole agent used [6, 8, 18–20, 24, 26–29]. Sec-
ond line therapy was initiated in the 4 cases (17 %) that
did not respond completely to prednisone and in the 9
cases where prednisone alone did not induce perman-
ent remission. In 3 of 4 cases not responding to pred-
nisone, the prednisone doses were adequate, however,
in 1 case the dosage was not mentioned. DMARDs
were attempted as steroid-sparing agents in 11 cases.
Mycophenolate mofetil was successful as a steroid-sparing
agent in 3 of the 5 cases in which it was used [7, 9, 10, 14,
16]. Azathioprine was a successful as a steroid sparing
agent in 2 of 4 cases in which it was used [5, 15, 17, 25],
while methotrexate was successful in 1 of 2 cases [9].
Because of disease relapse despite azathioprine, one
patient achieved clinical remission with 5 mg prednis-
one after high doses induction of prednisone [17].
Rituximab was initiated in 4 cases [8, 11, 13, 16] of
therapy refractory diseases leading to positive clinical
outcomes in all these cases. Two of these cases initi-
ated rituximab single therapy [8, 13], in one case meth-
ylprednisolone was combined with rituximab [11] and
in another case prednisone 10 mg daily was used as
maintenance therapy beside rituximab [16]. Adalimumab
[15] and cyclophosphamide [9] were both successfully
used in therapy refractory cases.
Discussion
In this systematic search of the literature we describe 25
published cases of IgG4-RD in children. The cases dem-
onstrate different organ manifestations of the disease
with different clinical outcomes emphasizing the broad
clinical spectrum of this disease.
Column1 Organ manifestation of IgG4RD in children(%) Column2 Column3 Column4 Column5
IgG4ROD 44
AIP1 12
IgG4-Rcholan 8
IgG4-Rpulmo 8
Remaining 28
44%
12%
8%
8%
28%
Organ manifestation of IgG4RD in
children (%)
IgG4-ROD
AIP1
IgG4Rcholangitis
IgG4R pulmonary disease
Remaining
Fig. 2 Organ manifestation of IgG4-RD in children. Remaining: Riedel’s thyroiditis/IgG4-related thyroid disease, IgG4-related sialadenitis,
IgG4-related mesenteritis, IgG4-related lymphadenopathy, IgG4-related dacryoadenitis, IgG4-related sinonasal disease and IgG4-related
hepatic mass
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Epidemiology
IgG4-RD is a rare and recently recognized fibro-
inflammatory condition of which the diagnosis is often
delayed or unrecognized because of unawareness. Gener-
ally it occurs in middle aged patients, more often in men
than women [1]. However, in this study we identified
more female patients than male patients. In children
IgG4-RD is even more uncommon and will subsequently
lead to significant delayed or unrecognized disease. All
cases identified with this systematic review have been
only recently published demonstrating that awareness is
increasing in pediatricians. One can postulate that the
average age of patients is lower than suggested [1], and
may be more frequent in the pediatric age group than
these 25 published cases might suggest.
Symptoms and organ manifestation
The symptoms of IgG4-RD are variable and depend on the
affected organs. It can be localized almost everywhere
(Table 2). In adults, IgG4-RD mostly affects the orbit, the
salivary tract, the pancreas and the lymph nodes, however,
manifestations in almost every part of the human have been
described [2]. In this study we have demonstrated a similar
distribution of disease localizations in children. As in adults,
most pediatric patients had orbital or pancreatic localiza-
tions. Therefore, IgG4-RD in children apparently is the
same entity as in adults. In cases of unexplained inflamma-
tory conditions, especially when tumor-like abnormalities
are observed by physical examination or imaging studies in
the preferential localization of the disease (pancreas, saliv-
ary glands, orbit, lymph nodes), one should rule out IgG4-
RD. Furthermore, conditions previously called Mikulicz’ s
disease, sclerosing sialadenitis, inflammatory orbital
pseudotumor or any pseudotumor, a subset of idiopathic
retroperitoneal fibrosis and Riedel’s thyroiditis are now
mostly reclassified as IgG4-RD and should raise suspicion
for IgG4-RD [30].
Diagnosis
The diagnosis of IgG4-RD can only be confirmed histo-
logically, the gold standard, while clinical symptoms,
serological and radiological findings could be supportive
to establish the diagnosis. The typical histological abnor-
malities (Fig. 3), according to the Boston consensus [31],
are dense lymphoplasmacytic infiltrate, storiform fibrosis
and obliterative phlebitis. The ratio of IgG4/IgG positive
plasma cells in tissues should be greater than 0.4 and
the numbers of IgG4 positive plasma cells per high
Table 2 Organ manifestations of IgG4-related disease
Pancreas
Autoimmune pancreatitis type 1
Lymph nodes
Ig4-related lymphadenopathy of several lymph nodes
Liver and bile duct
IgG4-related sclerosing cholangitis
IgG4-related cholecystitis
IgG4-related hepatopathy
Other abdominal manifestations
Inflammatory pseudotumors
Retroperitoneal fibrosis
Small bowel obstruction caused by peritoneal IgG4-RD
IgG4-RD of stomach with chronic ulcer
IgG4-related esophagitis
Kidneys
Interstitial nephritis
Glomerular lesions such as
membranous nephropathy
Skin manifestation
Erythematous, subcutaneous papules or nodules of IgG4 origin
Urological manifestation
IgG4-related prostatitis
Ureteral IgG4-RD
Testicular inflammation as a
manifestation of IgG4-RD
Orbital and ophthalmic manifestation
Inflammatory pseudotumors of orbit
Scleritis
Retinopathy due to IgG4-RD with
hypergammaglobulinemic hyperviscosity
Trigeminal and orbital nerve compression
Nasolacrimal duct obstruction
Pulmonary manifestation
Interstitial lung disease/interstitial pneumonia
Bronchial damage/asthma-like clinical presentation
Plural manifestation of IgG4-disease
Pulmonary arterial hypertension
Cardiovascular manifestation
IgG4-related periaortitis
IgG4-related aortitis
Pericarditis
IgG4-related coronary artery disease
Thyroid
Riedel’s thyroiditis
Fibrosing Hashimoto thyroiditis
Salivary and lacrimal gland
IgG4-RD Mikulicz’s
Küttner's tumor or IgG4-related submandibular gland disease
Nervous system
Infundibular hypophyistis
Hypertrophic pachymeningitis
IgG4-related hypophysitis
Intracerebral inflammatory pseudotumors
Neuropathy
Other manifestations
IgG4-related fibrosing mediastinitis
IgG4-related myositis
Multifocal fibrosclerosis
Increased risk of malignancy: lung, colon
and especially MALT lymphoma.
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power field (HPF) should be greater than the numbers
agreed in the consensus [31]. IgG4 positive plasma cells
in tissues could also be observed in several other condi-
tions without meeting the histological diagnostic criteria
for IgG4-RD. Therefore, alternative diagnosis such as
xanthogranulomatous disease, granulomatosis with poly-
angiitis and sarcoidosis should be excluded before
obtaining the diagnosis IgG4-RD [32]. In current study,
almost all cases were histologically proven, except a case
of Riedel’s thyroiditis, which is recently been recognized
as a spectrum of IgG4-RD [21].
Serum IgG4 is elevated in most of the cases of IgG4-
RD, but about 30 to 50 % of histologically confirmed
cases have normal levels of serum IgG4, which can lead
to falsely rejecting the diagnosis [30]. A similar percent-
age of pediatric patients had elevated serum IgG4 levels
(70 %) to those reported in the adult population. In gen-
eral the specificity and positive predictive value of serum
IgG4 are low, but if elevated can be useful in monitoring
response to treatment [31]. Inflammatory biomarkers
such as erythrocyte sedimentation rate and C-reactive
protein might be elevated, but normal levels of these
biomarkers are frequently observed in IgG4-RD making
them less specific as biomarkers [33]. Moreover, re-
cently, serological studies of IgG4 positive circulating
plasmablasts have been shown to be superior to serum
IgG4 levels in IgG4-RD [34]. So far this technique has
not been widely introduced for clinical applications.
Pathogenesis
The pathogenesis of IgG4-RD is unclear. Generally abun-
dant serological T-helper cells 2 and regulatory T-cells are
observed. These are most probably induced by an antigen
triggering the immune system [1]. Subsequently, interleu-
kin (IL)-4,5,10,13 and transforming growth factor (TGF)-
beta have been assumed to activate B-cells, hence produ-
cing IgG4 expressing B-cells and fibrosis [1]. The role of
IgG4 antibodies in the pathogenesis is unclear, but
because of characteristics of these antibodies [35], they
most probably act as anti-inflammatory antibodies as re-
sponse to an unknown trigger (Fig. 4).
Treatment
When untreated, IgG4-RD can cause irreversible organ
damage hence early and aggressive treatment is indi-
cated [36]. Glucocorticoids are the first choice of the
treatment for the adults, mostly effective at a prednisone
dosage of 0.5 -1 mg/kg/day, adjusted according to ag-
gressive disease [37]. In the presented study prednisone
appeared first choice therapy for pediatric IgG4-RD.
There is no consensus on prednisone dosage in
pediatrics, but in general prednisone 1 to 2 mg/kg/day
should be appropriate. Prednisone can thereafter be ta-
pered according to individual response. Treatment with
prednisone is often rapidly effective, but this treatment
should be maintained for 2 to 4 weeks after initiation. In
the presented study prednisone was generally effective
first line therapy in 83 % of the cases. However, only in
43 % of the cases prednisone single therapy sufficed. The
rest of the cases required maintenance (immunosuppres-
sive) therapy. According to previous studies, especially
on adults, about 25 % of patients show relapse of the
disease despite prednisone maintenance therapy making
steroid sparing agents necessary [37]. MMF, azathioprine
and methotrexate were effective in about 50 % of the
cases in this study. The role of DMARDs in the treat-
ment of IgG4-RD is not yet clear and management of
this disease with these agents has not been outlined
[37]. Recently, increasing evidence for the efficacy of ri-
tuximab treatment of IgG4-RD has been demonstrated
[38]. In this review four patients were treated with ritux-
imab leading to significant clinical outcomes in all cases.
We recommend rituximab as a strong alternative when
a patient is refractory to therapy. Intravenous or sub-
cutaneous immunoglobulin treatment has been success-
fully used in other inflammatory or immune mediated
Fig. 3 Histology of the orbital tissue of an adult patient from our hospital with IgG4-related orbital disease. a HE-staining demonstrating multiple
lymphoid infiltrates and fibrosis. b Immunohistochemical staining for IgG showing diffuse scattered IgG (brown color). c Immunohistochemical
staining for IgG4 revealing widely scattered IgG4 positive plasma cells (dark brown) with an average of 339 per HPF out of 2 HPF with a ratio of
0.67 to total IgG plasma cells in the tissue. HE = Hematoxylin and Eosin, HPF = High-power field
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diseases, but this therapy has not yet been applied in
IgG-RD [39].
Serum IgG4, when elevated, can be used in disease ac-
tivity monitoring after initiating treatment, however, the
role of serum IgG4 as disease activity marker has not yet
fully been outlined [1]. Studies should define the role of
serum IgG4 as disease marker, same applies to circulat-
ing plasmablasts. Imaging studies, especially PET scan is
useful in disease monitoring. Studies have shown the
usefulness of FDG-PET/CT scan for diagnosis, staging
and the degree of organ involvement and monitoring of
therapy response, and this imaging method seems to de-
tect more lesions than conventional methods like ultra-
sonography and CT [40].
Conclusion
In conclusion, IgG4-RD is a relatively new disease and
generally unknown to pediatricians. The results of this
study suggest that the average age of patients is lower
than suggested in the literature. Early recognition and
therapy are important to prevent serious and irreversible
organ damage. Treatment with prednisone is the first choice
for this disease, but maintenance therapy with DMARDs is
often required. Rituximab may be a good alternative in ther-
apy refractory disease. Further (epidemiological) studies
should confirm these preliminary conclusions. Moreover,
serological and histological studies and studies on treatment
of children with IgG4-RD are needed in order to confirm
the same results in children compared with previous studies
performed in adults.
Appendix
Search terms used in the medical databases for the lit-
erature search in this systematic review on IgG4-RD in
pediatrics.
Embase.com (251)
(‘immunoglobulin G4 related disease’/exp OR ‘Mikulicz
disease’/exp OR ((G4 OR igg4 OR ‘igg 4′ OR Mikulicz
OR kuttner OR riedel*) NEAR/3 (rd OR related OR
associat* OR autoimmun* OR disease* OR inflammat*
OR tumor* OR thyroidit*)):ab,ti) AND (child/exp OR
newborn/exp OR adolescent/exp OR adolescence/exp
OR ‘child behavior’/de OR ‘child parent relation’/de OR
pediatrics/exp OR childhood/exp OR ‘child nutrition’/de
OR ‘infant nutrition’/exp OR ‘child welfare’/de OR ‘child
abuse’/de OR ‘child advocacy’/de OR ‘child develop-
ment’/de OR ‘child growth’/de OR ‘child health’/de OR
‘child health care’/exp OR ‘child care’/exp OR ‘childhood
disease’/exp OR ‘child death’/de OR ‘child psychiatry’/de
OR ‘child psychology’/de OR ‘pediatric ward’/de OR
‘pediatric hospital’/de OR ‘pediatric nursing’/exp OR
‘pediatric anesthesia’/exp OR ‘pediatric surgery’/exp OR
(adolescen* OR infan* OR newborn* OR (new NEXT/1
born*) OR baby OR babies OR neonat* OR child* OR
kid OR kids OR toddler* OR teen* OR boy* OR girl* OR
minors OR underag* OR (under NEXT/1 (age* OR
aging)) OR juvenil* OR youth* OR kindergar* OR puber*
OR pubescen* OR prepubescen* OR prepubert* OR
pediatric* OR paediatric* OR school* OR preschool* OR
highschool* OR picu OR nicu OR picus OR nicus):ab,ti)
Medline (224)
(Mikulicz’ Disease/OR ((G4 OR igg4 OR igg 4 OR Mikulicz
OR kuttner OR riedel*) ADJ3 (rd OR related OR associat*
OR autoimmun* OR disease* OR inflammat* OR tumor*
OR thyroidit*)).ab,ti.) AND (exp child/OR exp infant/OR
adolescent/OR exp pediatrics/OR exp Child Health Ser-
vices/OR Hospitals, Pediatric/OR (adolescen* OR infan*
OR newborn* OR (new ADJ born*) OR baby OR babies
OR neonat* OR child* OR kid OR kids OR toddler* OR
teen* OR boy* OR girl* OR minors OR underag* OR
(under ADJ (age* OR aging)) OR juvenil* OR youth* OR
kindergar* OR puber* OR pubescen* OR prepubescen* OR
prepubert* OR pediatric* OR paediatric* OR school* OR
preschool* OR highschool*).ab,ti.)
Cochrane (6)
(((G4 OR igg4 OR ‘igg 4’ OR Mikulicz OR kuttner OR
riedel*) NEAR/3 (rd OR related OR associat* OR
Fig. 4 Proposed mechanism of the formation of IgG4 antibodies by ‘’Fab-Arm” exchange. IgG4 antibodies continuously exchange half molecules
with other antibodies making them bivalent reactive antibodies with two different antigen-binding fragments. These antibodies are also unable
to activate the classical complement system and can bind to antigens. However, as a result of bivalent reactivity unable to form immune complexes.
Because of these characteristics the IgG4 antibodies are most probably anti-inflammatory agents rather than pro-inflammatory. Fab = antigen
binding fragment
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autoimmun* OR disease* OR inflammat* OR tumor*
OR thyroidit*)):ab,ti) AND ((adolescen* OR infan* OR
newborn* OR (new NEXT/1 born*) OR baby OR babies
OR neonat* OR child* OR kid OR kids OR toddler* OR
teen* OR boy* OR girl* OR minors OR underag* OR
(under NEXT/1 (age* OR aging)) OR juvenil* OR
youth* OR kindergar* OR puber* OR pubescen* OR
prepubescen* OR prepubert* OR pediatric* OR paedi-
atric* OR school* OR preschool* OR highschool* OR
picu OR nicu OR picus OR nicus):ab,ti)
Web-of-science (126)
TS = ((((G4 OR igg4 OR “igg 4” OR Mikulicz OR kuttner
OR riedel*) NEAR/2 (rd OR related OR associat* OR
autoimmun* OR disease* OR inflammat* OR tumor* OR
thyroidit*))) AND ((adolescen* OR infan* OR newborn*
OR (new NEAR/1 born*) OR baby OR babies OR neo-
nat* OR child* OR kid OR kids OR toddler* OR teen*
OR boy* OR girl* OR minors OR underag* OR (under
NEAR/1 (age* OR aging)) OR juvenil* OR youth* OR
kindergar* OR puber* OR pubescen* OR prepubescen*
OR prepubert* OR pediatric* OR paediatric* OR school*
OR preschool* OR highschool* OR picu OR nicu OR
picus OR nicus)))
PubMed publisher (33)
(Mikulicz’ Disease[mh] OR ((G4[tiab] OR igg4[tiab] OR
“igg 4”[tiab] OR Mikulicz[tiab] OR kuttner[tiab] OR rie-
del*[tiab]) AND (related[tiab] OR associat*[tiab] OR
autoimmun*[tiab] OR disease*[tiab] OR inflammat*[tiab]
OR tumor*[tiab] OR thyroidit*[tiab]))) AND (child[mh]
OR infant[mh] OR adolescent[mh] OR pediatrics[mh]
OR Child Health Services[mh] OR Hospitals, Pedia-
tric[mh] OR (adolescen*[tiab] OR infan*[tiab] OR new-
born*[tiab] OR new born*[tiab] OR baby OR babies OR
neonat*[tiab] OR child*[tiab] OR kid OR kids OR tod-
dler*[tiab] OR teen*[tiab] OR boy*[tiab] OR girl*[tiab]
OR minors OR underag*[tiab] OR under age*[tiab] OR
under aging*[tiab] OR juvenil*[tiab] OR youth*[tiab] OR
kindergar*[tiab] OR puber*[tiab] OR pubescen*[tiab] OR
prepubescen*[tiab] OR prepubert*[tiab] OR pediatric*[-
tiab] OR paediatric*[tiab] OR school*[tiab] OR pre-
school*[tiab] OR highschool*[tiab])) AND (publisher[sb]
OR inprocess [sb])
Google scholar (100)
“G4|igg4|Mikulicz|kuttner|riedel rd|related|associat|au-
toimmune|disease|inflammation|tumor|thyroiditis” chil
d|children|adolescent|adolescents|adolescence|infant|in
fants|infancy
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